TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8567514
Drug: HCHO+MCT trial
Normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCHO+MCT trial (high CHO (HCHO) 214 g + 29 g MCT suspension)
Study: 8567514
Drug: MCT trial
Normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT trial (29 g MCT solution)
Study: 25062747
Drug: internet-based cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-based cognitive-behavioural therapy (iCBT)
Study: 20120778
Drug: Enalapril (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (40 mg/day)
Study: 20120778
Drug: Losartan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (200 mg/day)
Study: 16357312
Drug: Rosiglitazone 8
Normalized name: rosiglitazone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 8 mg daily
Study: 15215284
Drug: Monthly weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly weight fluctuations
Study: 11215231
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine 2 ml added to 1% propofol 20 ml (Group L)
Study: 11215231
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2 ml added to 1% propofol 20 ml (Group S)
Study: 8157036
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg b.d. for 12 weeks and fluvastatin 20 mg AM + 40 mg PM for an additional 12 weeks (Group A)
Study: 8157036
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg qPM during the entire study (Group B)
Study: 8157036
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of Group A (60 mg) vs Group B (40 mg qPM)
Study: 28264693
Drug: Tailored programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored programme for implementing recommendations for multimorbid patients with polypharmacy; includes structured medication counselling, medication lists, and medication reviews.
Study: 18039681
Drug: Step-down treatment
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down treatment (COBRA regimen: sulphasalazine 2 g daily, methotrexate 15 mg weekly, oral prednisolone starting at 60 mg daily, tapering to 7.5 mg over 6 weeks)
Study: 18039681
Drug: Step-up treatment
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up treatment (DMARD monotherapy)
Study: 16413428
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg ddAVP
Study: 16413428
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg ddAVP
Study: 9328363
Drug: Low-dose rHuEPO
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rHuEPO (1,500 U intravenously three times a week for 26 weeks)
Study: 9328363
Drug: Low-dose rHuEPO
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rHuEPO plus nandrolone decanoate (100 mg intramuscularly weekly)
Study: 8405026
Drug: Pinacidil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil 0.1 mg/kg IV
Study: 3533372
Drug: Piretanide (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide (24 mg daily for 28 days)
Study: 31444820
Drug: S1 implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: S1 implants
Study: 31444820
Drug: S2 implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: S2 implants
Study: 23965696
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.25% bupivacaine (nerve block of the infrapatellar branch of the saphenous nerve)
Study: 14708961
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with other drugs (cefepime, glycopeptide, linezolid)
Study: 19563201
Drug: Method with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method with standard treatment lines
Study: 17805064
Drug: Irinotecan, carboplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan, carboplatin, and imatinib (600 mg/day); treatment cycles were 28 days.
Study: 9507618
Drug: Physiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy treatment regimen
Study: 8589024
Drug: 5-fluorouracil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil at 300 mg/m2 and folinic acid at 200 mg/m2 daily for five days
Study: 31823525
Drug: Tropifexor (LJN452)
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor (LJN452) 300 µg with high-fat meal
Study: 31075314
Drug: Moderate-intensity aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity aerobic training (6 months, thrice weekly)
Study: 27790726
Drug: GP2015 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP2015 (50 mg s.c. injection)
Study: 27790726
Drug: GP2015 via
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP2015 via autoinjector (AI) (50 mg s.c. injection)
Study: 27790726
Drug: ETN (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN (50 mg s.c. injection)
Study: 27790726
Drug: GP2015 via
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP2015 via prefilled syringes (PFS) (50 mg s.c. injection)
Study: 26448615
Drug: Adjunctive aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive aripiprazole treatment (10 mg/day)
Study: 21828950
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg) in BOS (+) group (n = 4)
Study: 21828950
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg) in BOS (−) group (n = 4)
Study: 19854375
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil (2 g/d)
Study: 19854375
Drug: Menhaden oil
Normalized name: MENHADEN OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menhaden oil (2 g/d)
Study: 15566659
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg pamidronate (group A)
Study: 15566659
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg pamidronate (group B)
Study: 9217246
Drug: Virend (15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virend (15% ointment)
Study: 2906474
Drug: Olsalazine (0.75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine (0.75, 1.5, or 3 g daily)
Study: 2906474
Drug: Olsalazine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine (1.5 g and 3 g daily)
Study: 19789443
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (hemoglobin <70 g/L)
Study: 19789443
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (hemoglobin <95 g/L)
Study: 18609051
Drug: Liberal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluid prescription (30-35 ml/kg body weight/day)
Study: 18609051
Drug: Restrictive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluid prescription (maximum fluid intake of 1.5 L/day)
Study: 8987919
Drug: Vaginal approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal approach with bilateral sacrospinous vault suspension and paravaginal repair
Study: 8987919
Drug: Abdominal approach
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal approach with colposacral suspension and paravaginal repair
Study: 1455374
Drug: Pulse therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse therapy with methylprednisolone 25‐30 mg/kg/day for 3 consecutive days combined with cyclophosphamide 0.4‐0.5 g/sq. m BSA on the 3rd day, repeated quarterly for 12 months (Group 1 and Group 2)
Study: 1455374
Drug: No pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pulse therapy (Group 3)
Study: 25269124
Drug: Cognitive processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive processing therapy (n = 32)
Study: 25269124
Drug: Present centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present centered therapy (n = 13)
Study: 22020317
Drug: S-1 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 administered under fed conditions
Study: 22020317
Drug: S-1 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 administered under fasting conditions
Study: 19710195
Drug: Milk group
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk group (3-5 portions of dairy products daily)
Study: 17261227
Drug: Walnut-supplemented diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut-supplemented diet (≥ 28 g of walnuts per day)
Study: 17261227
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (≥ 2 g of walnuts per day)
Study: 15330755
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (1 g of L‐ascorbate, 400 IU of D,L‐alpha‐tocopherol acetate, 600 mg of alpha‐lipoic acid)
Study: 9554641
Drug: High-frequency oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency oral airway oscillation (frequency 8 Hz; I:E ratio 9:1)
Study: 9554641
Drug: High-frequency oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency oral airway oscillation (frequency 14 Hz; I:E ratio 8:1)
Study: 9554641
Drug: Conventional chest
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional chest physical therapy (CPT)
Study: 24897743
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (PT group) - six sessions of a standardized hospital-based physical therapy program
Study: 24897743
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (no-PT group)
Study: 24897743
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (PT group)
Study: 20722677
Drug: Tramadol (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (37.5 mg)/Acetaminophen (325 mg)
Study: 20722677
Drug: Tramadol/Acetaminophen
Normalized name: TRAMADOL/ACETAMINOPHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/Acetaminophen
Study: 19041063
Drug: ATO 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATO 0.15 mg/kg i.v. x 7 days + melphalan 200 mg/m2 i.v. over 2 days + AA 1000 mg i.v. over 7 days
Study: 19041063
Drug: ATO 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATO 0.25 mg/kg i.v. x 7 days + melphalan 200 mg/m2 i.v. over 2 days + AA 1000 mg i.v. over 7 days
Study: 19041063
Drug: No ATO
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ATO + melphalan 200 mg/m2 i.v. over 2 days + AA 1000 mg i.v. over 7 days
Study: 19041063
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms (ATO + AA + melphalan)
Study: 8824689
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg nefazodone once daily in the morning (treatment 1)
Study: 8824689
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg nefazodone once daily in the evening (treatment 2)
Study: 8824689
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg nefazodone twice daily (treatment 3)
Study: 1454350
Drug: Augmentation laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation laser panretinal photocoagulation (MORE)
Study: 1454350
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (NOMORE)
Study: 3966664
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with bupivacaine 0.25 mg X kg‐1
Study: 3966664
Drug: Bupivacaine 0.25
Normalized name: levobupivacaine 0.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25 mg X kg‐1 im without surgery (volunteers)
Study: 24662322
Drug: Anti-CGRP monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CGRP monoclonal antibody (up to 2000 mg)
Study: 20712261
Drug: levobupivacaine-hyaluronidase 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine-hyaluronidase 10 IU x ml(‐1)
Study: 20712261
Drug: racemic bupivacaine-hyaluronidase
Normalized name: Racemic bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: racemic bupivacaine-hyaluronidase 10 IU x ml(‐1)
Study: 10975012
Drug: Ofloxacin (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (total 15 mg/kg, 2 doses)
Study: 10975012
Drug: Nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalidixic acid (NA: 55 mg/kg daily for 5 days)
Study: 1574933
Drug: Whole-body cold
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body cold therapy
Study: 1574933
Drug: Hot mud-pack
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot mud-pack therapy
Study: 3882071
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of contrast material (60 to 350 mL)
Study: 3882071
Drug: No infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No infusion of contrast material
Study: 3882071
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of contrast material in high-risk group
Study: 3882071
Drug: No infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No infusion of contrast material in high-risk group
Study: 30353444
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg + Morphine
Study: 28183002
Drug: TSB-based phototherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSB-based phototherapy treatment
Study: 23320487
Drug: oral atypical
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral atypical antipsychotic medication
Study: 15545855
Drug: 4 doses
Normalized name: parathyroid hormone 25 MCG/Dose Cartridge, 14 Doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 doses of Pn‐PD at 2, 4, 6 and 12‐15 months
Study: 15545855
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of Pn‐PD at 2, 4 and 6 months and 1 dose of 23‐valent polysaccharide vaccine (PncPS) at 12‐15 months
Study: 15545855
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of hepatitis B vaccine at 2, 4 and 6 months and Pn‐PD at 12‐15 months
Study: 10770194
Drug: Metyrapone administration
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metyrapone administration in normal men; n = 8
Study: 10770194
Drug: Replacement therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacement therapy in patients with chronic hypocortisolism; n = 8
Study: 9327779
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg QD for 12 weeks increasing to 20 mg QD for 12 weeks
Study: 9327779
Drug: Fenofibrate 100
Normalized name: fenofibrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 100 mg TID for 24 weeks
Study: 26888908
Drug: Ertapenem (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem (1.0 g once daily)
Study: 26888908
Drug: Piperacillin/tazobactam (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (4.5 g every 8 h)
Study: 22770792
Drug: 10‐mL 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mL 1% lidocaine paracervical block
Study: 16219143
Drug: Combination (TCM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (TCM plus NP regimen)
Study: 7832387
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (RHE) at a loading dose of 300 U/kg iv 3 times/week for 1 week followed by 150 U/kg 3 times/week (N = 13) or 100 U/kg 3 times/week (N = 7)
Study: 1977080
Drug: Low-dose zidovudine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose zidovudine (300 mg daily)
Study: 1977080
Drug: Medium-dose zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium-dose zidovudine (600 mg daily)
Study: 1977080
Drug: High-dose zidovudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose zidovudine (1500 mg daily)
Study: 1977080
Drug: Acyclovir (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (4.8 g) with zidovudine
Study: 1977080
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of zidovudine (300 mg, 600 mg, 1500 mg)
Study: 344850
Drug: Theophylline 125
Normalized name: theophylline 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 125 mg
Study: 344850
Drug: Ephedrine SO4
Normalized name: EPHEDRINE SO4 25MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine SO4 30 mg
Study: 26686385
Drug: hIL1bQb vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hIL1bQb vaccine (900 µg, six injections)
Study: 26686385
Drug: hIL1bQb vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hIL1bQb vaccine
Study: 23039299
Drug: Magnesium (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (10 mmol bolus, 5 mmol/h infusion for 6 hours)
Study: 17325559
Drug: Alanyl-glutamine (AG)
Normalized name: Alanyl glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alanyl-glutamine (AG) 24 g/d for 10 days
Study: 17325559
Drug: Glycine (G)
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine (G) 25 g/d for 10 days (control)
Study: 16562417
Drug: Individual TLFB
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual TLFB administration
Study: 16562417
Drug: Group TLFB
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group TLFB administration
Study: 12196420
Drug: Purified t10c12
Normalized name: Purified oxgall
DrugBank: Ox bile extract (DB14016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified t10c12 CLA (3.4 g/day)
Study: 12196420
Drug: CLA mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLA mixture (3.4 g/day)
Study: 7572573
Drug: Various predictors
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various predictors including thrombolysis, coronary artery bypass grafting, diuretic use, heart rate, calcium channel blocker use, QRS duration
Study: 2692821
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate 0.05% cream, augmented formulation (AF), once-daily application
Study: 2692821
Drug: Fluocinonide 0.05%
Normalized name: FLUOCINONIDE 0.05% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocinonide 0.05% cream, twice-daily application
Study: 57451
Drug: 1 alpha‐hydroxycholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 alpha‐hydroxycholecalciferol (1alpha‐H.C.C.) 1 mug daily for eleven weeks
Study: 31859682
Drug: Clinically meaningful
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically meaningful use (combination of learning, goal setting, and self-tracking)
Study: 23874586
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiation in 10 fractions of 3 Gy, 5 fractions a week for 2 consecutive weeks with oral capecitabine 700 mg/m² twice daily throughout radiation therapy
Study: 15558087
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush and chlorhexidine gluconate (CHX) spray (Group MC)
Study: 15558087
Drug: Electrically powered
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrically powered toothbrush and CHX spray (Group EC)
Study: 15558087
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate (CHX) spray (Group C)
Study: 10529323
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin group
Study: 7768249
Drug: Somatostatin (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (IV loading dose 125 micrograms, followed by IV infusion of 125 micrograms.h‐1)
Study: 7419830
Drug: Lodoxamide tromethamine
Normalized name: Lodoxamide Tromethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodoxamide tromethamine (0.01 mg)